Syncona
在场
是其中之一......
Syncona 是一家在股票代码 SYNC (GB) 下上市的公司。
Syncona 在 3 个国家有直接业务。Syncona 拥有 13家子公司，其中包括 Achilles Therapeutics、Anaveon 和 Autolus Therapeutics。
他们在：
高管
查看带有其 207 名主要高管的组织结构图
Syncona 搜索最多的简介
- Chris Hollowood, Chief Executive Officer
- Gian Piero Reverberi, Non-Executive Director
- Kemal Malik, Non-Executive Director
高管在Syncona变化
- John RocheJohn Roche 将于202410月1作为 Non-Executive Director 加入公司 (新闻发布的2024九月20号).
创建提醒
跟踪 Syncona 的高管变动
控股公司
Syncona 拥有 1,328 家竞争者，其中包括 Berkshire Hathaway (美国(美洲))、Amundi (法国) 和 Apollo Global Management (美国(美洲))。
Popular M&A news in 控股公司
- Alliance Witan的新名称是Alliance Witan。 (公布2024十月29号).
- Atria Wealth Solutions and LPL Financial have merged (公布2024十月2号)..
- Penn Mutual Midwest Wealth Strategies的新名称是1847 Financial。 (公布2024九月19号).
控股公司 行业的其他推荐联系人
消息
Syncona 的最新新闻稿
- Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel - obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
- Resolution Therapeutics Announces New Clinical and Preclinical Data Showcasing Regenerative Macrophage Therapy at AASLD 2024
- Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations
- Kesmalea Therapeutics Appoints Robert Johnson as CEO To Lead Development of New Class of Oral, CNS Penetrant Protein Degraders
- News
- Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
- Purespring Therapeutics presents new preclinical data on novel gene therapy for IgA Nephropathy at ASN Kidney Week 2024
- Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for SBT101, its Gene Therapy Candidate in Adrenomyeloneuropathy (AMN)
- Anaveon announces presentation of new data on development compounds ANV700 and ANV600 at the Society for Immunotherapy of Cancer 2024 Annual Meeting
- Spur Therapeutics Showcases Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Oral Presentation at ESGCT 31st Annual Congress
- View more press releases Close
关于 Syncona 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Chris Hollowood 
